Referências

1. Bula de Pluvicto®. Acesso em 21/05/2024. Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=PLUVICTO. 2. Sartor O et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021 June; 385(12):1091–1103. 3. Dorff TB A et al. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. 4. Schmuck S et al. Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017 Dec;58(12):1962–1968. 5. Woythal N et al. Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer J Nucl Med. 2018 Feb;59(2):238–243. 6. Fizazi K et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):597-610. 7. Maffey-Steffan J, Scarpa L, Svirydenka A et al. The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695–712. 8. Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol. 2018 Jun;19(6):825–833.